Tier 2: Amplifier Mechanisms
These mechanisms cannot initiate ME/CFS independently but substantially worsen and perpetuate it once established. Addressing them reduces symptom burden, prevents crashes, and may improve tolerance of Tier 1-targeted treatments.
1 NAD⁺ Depletion Spiral
PARP hyperactivation from oxidative damage, CD38-mediated consumption by immune cells, and impaired kynurenine pathway conversion collectively deplete the NAD⁺ pool, amplifying energy failure and immune cell exhaustion.
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| NR (nicotinamide riboside) | NAD⁺ precursor; NAMPT-independent pathway | Supplement | A | Clinical use; Long COVID emerging data |
| NMN (nicotinamide mononucleotide) | NAD⁺ precursor; NMN transporter pathway | Supplement | A | Clinical use |
| NADH | Direct Complex I electron donor | Supplement | A | RCT: Castro-Marrero 2021, n=207 (with CoQ10) |
| CoQ10 (ubiquinol) | ETC support → PARP activation demand ↓ | Supplement | A | Clinical use; multiple studies |
| Riboflavin (B2) | FAD precursor for Complex II | Supplement | A | Clinical use |
| Spermidine | Mitophagy via PINK1/PRKN + histone acetylation | Supplement | A | Experimental; human cognition data emerging |
| Urolithin A | Mitophagy via lysosomal clearance of damaged mitochondria | Supplement | A | Experimental; no ME/CFS trials |
2 Oxidative Stress Vicious Cycle
Reactive oxygen species peroxidize cardiolipin, destabilising ETC supercomplexes and causing further electron leak — a self-amplifying loop. Elevated lipid peroxidation, 8-isoprostanes, and protein carbonyls are documented in ME/CFS (Maes et al. 2009).
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| CoQ10 (ubiquinol) | Antioxidant at ETC Complex II–III; lipid peroxidation ↓ | Supplement | A | Clinical; multiple studies |
| NAC (N-acetyl cysteine) | Glutathione precursor; ROS scavenger | Supplement | A | Clinical use |
| Alpha-lipoic acid (ALA) | Nrf2 activator; mitochondrial antioxidant; start low (paradoxical worsening risk) | Supplement | A/B | Clinical use |
| Omega-3 (EPA/DHA) | Membrane lipid protection; cardiolipin preservation | Supplement | A | Clinical use |
| Quercetin | Nrf2 activator; mast cell stabilizer | Supplement | A/B | Clinical use |
| Curcumin | NF-κB inhibition; Nrf2 activation (bioavailability issue) | Supplement | A/B | Clinical use; enhanced formulation required |
| Vitamin D3 | Immune regulation + antioxidant response | Supplement | A | Clinical; target 40–60 ng/mL |
| Zinc (glycinate) | SOD cofactor; gut barrier + antioxidant | Supplement | A | Clinical use |
| Resveratrol | Sirtuin/AMPK activator; mitochondrial biogenesis | Supplement | A/B | Experimental |
| PQQ | Mitochondrial biogenesis stimulator | Supplement | A | Preliminary evidence only |
| Photobiomodulation | CCO activation → NO inhibition ↓ → electron transport ↑ | Physical | A | Feasibility trial registered |
| HBOT | Oxidative stress ↓; mitochondrial ATP ↑; O₂ delivery restoration | Procedure | B | 2025 RCT promising |
3 Mast Cell–Energy Loop
Bidirectional activation: mast cell mediators worsen energy state; energy failure activates mast cells. This loop amplifies neuroinflammation, gut permeability, pain, and cognitive dysfunction. Mast cell activation does NOT produce PEM independently; it requires pre-existing energy dysfunction to drive the PEM cycle.
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| H1 antihistamines (cetirizine, loratadine) | H1 receptor blockade | Medication | B | Clinical |
| H2 antihistamines (famotidine, cimetidine) | H2 blockade + immune modulation | Medication | B | Clinical |
| Cromolyn sodium | Mast cell stabilizer; degranulation inhibition | Medication | B | Clinical, off-label |
| Ketotifen | Mast cell stabilizer + H1 blocker | Medication | B | Clinical, off-label |
| Quercetin | Mast cell stabilizer; Nrf2 | Supplement | A/B | Clinical use |
| PEA | PPAR-α → mast cell membrane stabilization | Supplement | B | Clinical, off-label |
| Amitriptyline (low-dose) | Mast cell mediator inhibition + sleep | Medication | B | Clinical |
| Low-histamine diet | Reduced histamine load; degranulation triggers ↓ | Dietary | A | Lifestyle; 2–4 week trial recommended |
5 Endothelial Activation and Microclotting
Thromboinflammation, endothelial dysfunction, and microclot formation cause tissue hypoxia, cerebral hypoperfusion, and exercise intolerance. This mechanism requires an upstream inflammatory trigger; it amplifies rather than initiates disease.
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| HELP apheresis | Fibrinogen precipitation + microclot removal | Procedure | C | Trial — uncontrolled retrospective, Long COVID n=31 |
| Plasma exchange (TPE) | Microclot + mediator + autoantibody removal | Procedure | C | Trial — Phase 2 RCT negative |
| Sulodexide | Endothelial glycocalyx restoration | Medication | B | Experimental |
| Statin + ARB combination | Endothelial protection + anti-inflammatory | Medication | B | Experimental |
| Triple anticoagulant protocol | Microclot dissolution (aspirin + clopidogrel + apixaban) | Medication | C | Experimental; high bleeding risk; single-group origin (Pretorius/Kell); not guideline-supported; significant medicolegal exposure for prescribing clinicians |
| Omega-3 (EPA/DHA) | Anti-platelet aggregation; endothelial membrane protection | Supplement | A | Clinical use |
6 Dysautonomia and ANS Dysfunction
Orthostatic intolerance, POTS, impaired cerebral autoregulation, and parasympathetic/sympathetic imbalance perpetuate cerebral hypoperfusion and exercise intolerance. Documented in the majority of ME/CFS patients; one of the most tractable Tier 2 targets.
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| Pyridostigmine (Mestinon) | AChE inhibitor → vagal tone ↑, HR ↓ | Medication | B | Clinical, off-label; paradoxical worsening at high doses |
| Fludrocortisone | Mineralocorticoid → plasma volume expansion | Medication | B/C | Clinical; potassium monitoring required |
| Midodrine | α1-agonist → vasoconstriction ↑ | Medication | B/C | Clinical |
| Ivabradine | HCN channel → HR reduction (POTS) | Medication | B | Clinical, off-label |
| Propranolol / metoprolol | β-blocker for hyperadrenergic POTS | Medication | B | Clinical |
| High sodium + electrolytes | Plasma volume loading | Supplement | A | Clinical; 8–12 g sodium daily; contraindicated in hypertension, heart failure, renal disease |
| Compression garments | Venous return ↑; orthostatic pooling ↓ | Physical | A | Clinical |
| Stellate ganglion block (SGB) | Sympathetic denervation C6–C7; vasoconstriction ↓; ANS reset | Procedure | B | Trial — uncontrolled case series; no RCT |
| tVNS / taVNS | Parasympathetic tone ↑; sympathetic ↓; HRV ↑ | Neuromodulation | A | RCT feasibility; ongoing RCTs |
| Guanfacine | α2A-AR agonism → sympathetic ↓; prefrontal cortex ↑ | Medication | B | Experimental; no RCT |
| Nicotine (transdermal) | α7-nAChR → cholinergic anti-inflammatory + ANS | Neuromodulation | B | Experimental (n=4) |
| Acupuncture | ANS modulation; HRV ↑; NF-κB ↓ | Physical | A/B | Pilot RCTs; symptom-focused evidence |
| Far-infrared sauna (Waon) | CBF ↑; vascular function ↑; mitochondrial O₂ consumption ↑ (Hochecker 2025) | Physical | A/B | Small uncontrolled pilots (n=9-10); caution in severe dysautonomia; HSAT2 risk uncharacterized |
| Cold water immersion / cryotherapy | ANS reset; sympathetic recalibration | Physical | A/B | Pilot n=32; safety caution in POTS/dysautonomia |
| Taurine | Mitochondrial membrane stabilization; autonomic support | Supplement | A | Clinical use |
| Magnesium (glycinate/taurate) | NMDA modulation; 300+ enzyme cofactor; ANS support | Supplement | A | Clinical; moderate evidence |
7 Gut Dysbiosis
Butyrate-producer depletion → intestinal permeability ↑ → LPS translocation → systemic and neuroinflammatory immune activation. Whether severe dysbiosis (antibiotic-induced, post-gastroenteritis) can be a trigger-capable mechanism in a subset remains an open question.
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| Probiotics (Lactobacillus/Bifidobacterium) | Microbiome modulation; barrier support | Supplement | A | Clinical use |
| Saccharomyces boulardii | Post-antibiotic microbiome restoration | Supplement | A | Clinical use |
| Prebiotics (RS2, inulin) | Butyrate-producer substrate; contraindicated in SIBO | Supplement | A | Clinical use |
| Butyrate / tributyrin | SCFA → colonocyte fuel + enterochromaffin–vagal signal | Supplement | A | Clinical; strong mechanistic rationale |
| L-Glutamine | Gut barrier integrity; enterocyte fuel | Supplement | A | Clinical use |
| Low-FODMAP diet | Dysbiosis and IBS symptom management | Dietary | A | Clinical; 50–60% response in IBS comorbidity |
| Zinc (low-dose) | Tight junction integrity; gut barrier | Supplement | A | Clinical use |
| FMT (fecal microbiota transplant) | Microbiome reset | Procedure | B/C | Experimental; no ME/CFS RCT |
8 Epigenetic Consolidation
DNA methylation changes and histone modifications observed in ME/CFS patients may stabilize disease-promoting gene expression patterns. This is a hypothesis, not a confirmed mechanism: the observed methylation differences are cross-sectional and could reflect consequences of illness state, medication, or activity level rather than causal drivers (Trivedi et al. 2018). If valid, this mechanism would help explain why some patients who partially respond to Tier 1 interventions do not fully recover. A falsifiable prediction: methylation-stratified treatment trials should show that patients with high “consolidation signatures” fail treatments that low-signature patients respond to.
| Treatment | Mechanism of action | Category | Energy | Evidence |
|---|---|---|---|---|
| Rapamycin | mTOR inhibition → epigenetic aging ↓; histone modifications | Medication | B/C | Pilot — ~34% ITT; cross-tier mechanism |
| Spermidine | Histone acetylation modulation; autophagy induction | Supplement | A | Experimental; pre-clinical only |
| SAMe (S-Adenosylmethionine) | Methyl donor; supplies DNMT substrate; supports remethylation at hypomethylated loci | Supplement | A | Mixed ME/CFS evidence; dosing inadequately studied |
| Methyl-folate + methyl-B12 | MTHFR bypass; cofactor substrates for methylation cycle | Supplement | A | Clinical use; MTHFR genotype relevant |
| Betaine (trimethylglycine) | Alternative methyl donor; BHMT pathway bypasses folate cycle | Supplement | A | No ME/CFS data; mechanism extrapolated from homocystinuria |
| Riboflavin (B2) | MTHFR cofactor (FAD); enhances methyl-folate production in C677T carriers | Supplement | A | No ME/CFS data; genotype-stratified |
| Zinc | DNMT structural cofactor; deficiency impairs methylation maintenance | Supplement | A | Mild ME/CFS evidence; supplementation trials mixed |
Of all documented ME/CFS mechanisms, epigenetic consolidation has the fewest targeted treatment options. No approved therapy has been tested for its epigenetic effects in ME/CFS. Rapamycin and spermidine have relevant mechanisms but have not been studied in this context. The causal role of epigenetic changes in ME/CFS remains unproven — observed methylation differences (Trivedi et al. 2018) are cross-sectional and could be consequences rather than causes of disease.
The gain-vs-loss tension that previously divided the paper’s model has been resolved by the unified per-locus vector model in Chapter Formal Causal Hierarchy Analysis (Per-Locus Dynamics: Vector Model for Bidirectional Methylation). ME/CFS shows bidirectional methylation alterations: some loci hypermethylated, others hypomethylated. The vector model captures both via \(\mathbf{\mathcal{M}} \in [0, 1]^n\), with consolidation depth \(||\mathbf{\mathcal{M}} - \mathbf{\mathcal{M}}^\text{baseline}||\). In cancer, global DNMT3B redistribution (ProB → ProA/gene-region) produces both patterns simultaneously, making gain and loss complementary manifestations. For ME/CFS, the proposed mechanism is more targeted: HSAT2-specific loss-meCpG with loss of DNMT3B activity as a consequence of HSAT2 activation rather than global enzymatic redistribution (Geneviève Fourel, pers. comm. May 2026). The therapeutic implication is locus-dependent:
- Loss-dominant patients (\(||\mathbf{\mathcal{M}}_\text{ProB} - \mathbf{\mathcal{M}}_\text{ProB}^\text{baseline}||\) dominant): Remethylation strategies (DNMT3B activators, methyl donor support with SAMe, methyl-folate, methyl-B12, betaine). Demethylating agents (5-azacitidine, HDAC inhibitors, TET activators) are contraindicated — they would worsen existing hypomethylation at ProB repeats.
- Gain-dominant patients (\(||\mathbf{\mathcal{M}}_\text{ProA} - \mathbf{\mathcal{M}}_\text{ProA}^\text{baseline}||\) dominant): Energy restoration → passive demethylation after inflammation resolves.
- Mixed (most typical): Methyl-donor support (low-risk default) plus energy restoration. Locus-specific targeting (remethylation at ProB repeats + demethylation at hypermethylated promoters) is the principled ideal but requires pharmacological tools that do not yet exist.
Methyl-donor support (SAMe, methyl-folate, methyl-B12, betaine) represents the safest default strategy for all patients pending per-locus methylation profiling, since methyl donors support both methylation maintenance (preventing further ProB erosion, no harm at hypermethylated loci) and de novo remethylation at hypomethylated loci (potential benefit). Efficacy for ME/CFS symptoms remains unproven. For the full formal treatment including the DNMT3B zero-sum constraint (\(\sum_i \Delta m_i = 0\)), the irreversibility threshold \(m_i^\text{crit}\), the \(B_\text{strength}\) derived variable, and tissue/cell-type considerations, see Chapter Formal Causal Hierarchy Analysis Per-Locus Dynamics: Vector Model for Bidirectional Methylation.
Provisionality. The ProA/ProB repeat framework (Bonnet et al. 2026) is a preprint, developed in cancer, not peer-reviewed. Its extension to ME/CFS is our extrapolation, not endorsed by those authors.